Survodutide vs Somatropin (HGH)
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
SurvodutideGrowth Hormone PeptidesAnti-Aging & Longevity
Somatropin (HGH)- Summary
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- Somatropin is recombinant human growth hormone (rhGH), identical in structure to the 191-amino acid pituitary-derived growth hormone. It is FDA-approved for growth hormone deficiency, short stature, and wasting conditions. Off-label, it is widely explored for body composition, anti-aging, and performance enhancement, though significant risks accompany unsupervised use.
- Half-Life
- ~7 days
- 2-3 hours (subcutaneous); 20-30 minutes (intravenous)
- Admin Route
- SubQ
- Subcutaneous, Intramuscular (less common)
- Research
- —
- —
- Typical Dose
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- 0.15-0.3 mg/day (adults); titrated to IGF-1 levels
- Frequency
- Once weekly
- Once daily
- Key Benefits
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- Increases lean muscle mass and reduces body fat (particularly visceral)
- Restores growth hormone deficiency (FDA-approved)
- Improves bone mineral density
- Enhances exercise capacity and recovery
- Supports skin thickness and collagen synthesis
- Improves lipid profile in GHD patients
- Explored for anti-aging and cellular regeneration
- Side Effects
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Fluid retention and edema (common, dose-dependent)
- Carpal tunnel syndrome
- Joint and muscle pain
- Insulin resistance and elevated blood glucose
- +3 more
- Stacks With
- —
- —